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Background:  Sleep disturbances are common in individuals with diabetes. Patients with diabetes have higher rates of insomnia, 
excessive daytime sleepiness and increased incidence of restless leg syndrome. The purpose of our study was to investigate the 
prevalence and determine the predictors of sleep dysfunction in patients with type 2 diabetes in a southeast Asian Indian popu-
lation.
Methods:  We enrolled 120 patients with type 2 diabetes who attended an endocrinology clinic in a tertiary-care hospital. After 
we collected their demographic data, we recorded their anthropometric measurements. Fasting, postprandial blood glucose val-
ues and glycosylated hemoglobin (HbA1c) values were then obtained. Quality of sleep was evaluated in all the patients through 
the Pittsburgh Sleep Quality Index (PSQI), which is a questionnaire that assesses sleep quality and disturbances over a month-
long period. A Global Sleep Quality score ≥5 discriminates between good and poor sleepers.
Results:  The mean global PSQI score was 7.08 (standard deviation, 3.89), which suggested poor sleep quality in this population. 
Sixty-nine percent of patients had a global PSQI score ≥5, indicating that they were “poor sleepers.” The global PSQI score posi-
tively correlated with the duration of diabetes and was also independent of other variables such as age, gender, body mass index, 
HbA1c, or medications.
Conclusion:  We found a high prevalence of sleep dysfunction in patients with type 2 diabetes. We also found a significant corre-
lation between duration of diabetes and quality of sleep, independent of other variables. It is important for physicians to address 
the quality and duration of sleep in patients with type 2 diabetes.
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INTRODUCTION
Diabetes is a global health problem with significant human, 
social, and economic impacts. More than 300 million people 
worldwide live with diabetes. Each year, approximately 7 mil-
lion new patients develop diabetes. Sleep disturbances are com-
mon among individuals with diabetes. Patients with type 2 di-
abetes have been shown to have an increased prevalence of pe-
riodic breathing and time spent in rapid eye movement sleep. 
In addition, patients with diabetes are reported to have higher 
rates of insomnia, excessive daytime sleepiness and a higher 
incidence of restless leg syndrome. A majority of these patients 
may also have obstructive sleep apnea (OSA) [1]. OSA and di-
abetes mellitus share several risk factors, including advanced 
age and obesity [2]. Diabetes and OSA appear to be associated 
independent of the degree of adiposity [3-9]. Because both di-
abetes and OSA are associated with increased cardiovascular 
morbidity and mortality, it is possible that the presence of both 
conditions results in additive or even synergistic health risks 
[10]. To promote better management of type 2 diabetes, sleep 
disorders must be addressed in these patients. Identifying 
sleep disturbances in type 2 diabetics and treating them early 
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may improve overall prognosis and quality of life.
  The present study was carried out to identify the prevalence 
of sleep disturbances among patients with type 2 diabetes in a 
southeast Asian Indian population and to determine the pre-
dictors of sleep impairment in this population using a validat-
ed instrument, the Pittsburgh Sleep Quality Index (PSQI).
METHODS
Participants
The study was carried out at the Sri Ramachandra Medical 
Center, a tertiary-care teaching hospital in Chennai, South In-
dia. The study population was comprised of type 2 diabetes 
patients attending the Endocrine Outpatient Clinic. The total 
study sample included 120 patients; 96 had type 2 diabetes 
alone, and 24 had type 2 diabetes with co-existing hyperten-
sion. Patients who were diagnosed as having type 2 diabetes 
within the past year were excluded from the study, as were pa-
tients with other comorbidities like malignancy, renal disor-
ders, lung diseases, liver diseases, thyroid disorders, and cardi-
ac diseases. Smokers and alcoholics were also excluded from 
the study. Protocols and informed consent documents were 
approved by the Institutional Ethics Board in accordance with 
International and National Guidelines. All participants signed 
an informed consent form before inclusion in the study. The 
study period extended from September 2010 to February 2011. 
Data collection
For each patient, we recorded data regarding age, gender, du-
ration of diabetes, and use of medications. Height, weight, and 
waist circumference were measured in all participants; body 
mass index (BMI, kg/m
2) was calculated as weight divided by 
height squared. A detailed physical examination was then per-
formed. All vital signs were recorded. Fasting blood glucose 
(FBG), postprandial blood glucose (PPBG), and glycosylated 
hemoglobin (HbA1c) values were available for all the patients 
and were recorded from their case sheets. All the study patients 
were on anti-diabetic medications, either insulin or oral hypo-
glycemic agents or both.
Research tool
In all patients, quality of sleep was evaluated by administering 
the PSQI through an interview. The PSQI is a self-report ques-
tionnaire that assesses sleep quality and quantity over a month-
long period [11]. The questionnaire consists of 19 self-rated 
questions and 5 questions that should be answered by bed-
mates or roommates. The latter questions were used only for 
clinical information and were not used in the scoring. The 19 
questions were categorized into 7 components, which are 
graded on a scale that ranges from 0 to 3. The PSQI compo-
nents are as follows: subjective sleep quality (C1), sleep latency 
(C2), sleep duration (C3), habitual sleep efficiency (C4), sleep 
disturbances (C5), use of sleeping medication (C6), and day-
time dysfunction (C7). The sum of scores for these 7 compo-
nents yields one global PSQI score, which ranges from 0 to 21, 
where the highest score indicates the worst sleep quality. A 
global PSQI ≥5 has a diagnostic sensitivity of 89.6 and speci-
ficity of 86.5 in distinguishing “poor sleepers” (PSQI ≥5) from 
“good sleepers” (PSQI <5) [12]. The design of the PSQI is such 
that the items and the component scores represent standard 
areas of clinical focus in patients with reported sleep problems 
[13].
Statistical analysis
Statistical analysis was conducted with the SPSS version 17.1 
(SPSS Inc., Chicago, IL, USA). Quantitative variables were ex-
pressed as mean±standard deviation, and qualitative variables 
were expressed as percentage values. The scatter plot diagram 
was used to find the correlation of various variables with the 
global PSQI score. The R
2 value was obtained from the scatter 
plot from which the P value was determined. Logistic regres-
sion analysis was then applied to explore relationships between 
PSQI and other variables like age, gender, BMI, duration of di-
abetes, HbA1c, and choice of medications. For comparison 
between the three groups, we used the Kruskal-Wallis test. All 
tests were two-tailed, and we set the level of significance at P 
values of less than 0.05.
RESULTS
One hundred twenty patients completed the PSQI question-
naire and were included in the study. The demographic char-
acteristics of these patients are listed in Table 1. Our sample 
consisted of 55 females and 65 males. The mean age of the par-
ticipants was 53.9 years (standard deviation [SD], 9.2 years), 
and the average BMI was 27.09 kg/m
2 (SD, 5.3 kg/m
2). Fifty-
one patients (43%) were overweight (BMI, 25 to 29.9 kg/m
2), 
28 (23%) were obese (BMI ≥30 kg/m
2), and the remaining 41 
(34%) had a BMI <25 kg/m
2. 
  The mean PSQI score of the study patients was 7.08 (SD, 72
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3.89), and 69% (n=83) had a PSQI score ≥5, indicating poor 
quality of sleep. Individual components of PSQI are shown in 
Table 2. Of the seven components of PSQI, sleep latency was 
the most affected in our study population. Average sleep laten-
cy was 35.3 minutes (SD, 33.84), and the mean duration of 
sleep was 375.04 minutes (SD, 68.40). Global PSQI score did 
not differ significantly in hypertensive patients (7.04±3.17) 
compared to normotensive patients (7.17±4.09).
  A significant correlation was found between the duration of 
diabetes and the global PSQI score (R
2=0.181, P<0.05), indi-
cating that the duration of diabetes had a strong influence on 
sleep in our study sample (Fig. 1). This correlation was inde-
pendent of other variables like age, gender, BMI, HbA1c, or 
choice of medications, as shown in Table 3. Duration of diabe-
tes also had weaker correlations with the individual compo-
nents of the PSQI, of which subjective sleep quality correlated 
the most (R
2=0.123); however, this correlation was not statis-
tically significant. No significant correlation existed between 
HbA1c and global PSQI score. In contrast, there was a positive 
trend (R
2=0.03) between the two factors in patients with un-
controlled diabetes (HbA1c ≥7%). Other variables like BMI, 
age, gender, and choice of medications did not correlate with 
global PSQI score.
  Further analysis was done based on medications. Partici-
pants were divided into three groups: 1) patients who took only 
oral hypoglycemic agents (OHAs); 2) patients who took only 
insulin; and 3) patients who took both. Their respective PSQI 
Table 1. Participant characteristics 
Characteristic Females Males Overall
Age, yr  55.4±8.9 52.1±9.2 53.9±9.2
Weight, kg 67.06±12.50 69.74±11.0 68.06±13.02
Height, cm 153.73±6.70 162.90±7.01 158.75±8.26
BMI, kg/m
2 28.38±5.07 26.32±4.37 27.09±5.30
Waist circumfer-
ence, cm
92±9.9 96.6±9.9 94.5±10.2
FBG, mg/dL 148.50±43.34 180.30±73.01 165.72±63.03
PPBG, mg/dL 221.72±76.01 264.75±107.65 245.03±96.02
HbA1c, % 8.28±1.81 8.76±2.26 8.52±2.07
Mean duration of 
diabetes, yr
7.03±6.19 7.74±5.69 7.41±5.90
Global PSQI Score  7.18±3.87 6.98±3.92 7.08±3.89
Data are presented as mean±standard deviation.
BMI, body mass index; HbA1c, glycosylated hemoglobin; PSQI, Pitts-
burgh sleep quality index; FBG, fasting blood glucose; PPBG, post-
prandial blood glucose.
Table 3. Results of regression analysis 
Variable B  SE P 
value
Exp 
(B)
95% CI for 
Exp (B)
Lower Upper
Age 0.002  0.026 0.93 1.002 0.952 1.055
Sex -0.271  0.443 0.54 0.763 0.320 1.819
Duration of diabetes -0.196  0.062 0.02 0.822 0.728 0.928
Medications 0.078  0.302 0.79 1.081 0.599 1.952
BMI 0.017  0.048 0.73 1.017 0.926 1.116
HbA1c 0.004  0.109 0.97 1.004 0.811 1.242
R
2 (Cox & Snell’s) for this regression model was 0.132.
B, regression coefficient; SE, standard error; Exp (B), odds ratio; CI, 
confidence interval; BMI, body mass index; HbA1c, glycosylated he-
moglobin. 
Table 2. PSQI subcomponents distribution
PSQI component Value 
Subjective sleep quality 1.32±0.88
Sleep latency 1.48±1.09
Sleep duration 1.19±0.96
Sleep efficiency 0.58±0.77
Sleep disturbance 1.14±0.60
Hypnotic medication use 0.40±0.92
Daytime dysfunction 1.06±0.95
PSQI global score 7.08±3.89
Data are presented as mean±standard deviation.
PSQI, Pittsburgh sleep quality index.
Fig. 1. Correlation of global Pittsburgh sleep quality index 
(PSQI) score with duration of diabetes. 
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scores were 6.43±3.63 (only OHAs), 8.00±4.19 (only insulin), 
and 8.43±4.08 (both OHAs & insulin). Although the first group 
(only OHAs) had a low overall PSQI score compared to the 
other two groups, there was no statistically significant differ-
ence among the three groups in terms of individual compo-
nents (like subjective sleep quality, sleep latency) or global 
PSQI score (Table 4).
DISCUSSION
Our results suggest that there is a high prevalence of sleep dys-
function in patients with type 2 diabetes. In our study, a high 
proportion (69%) of type 2 diabetics had a PSQI score ≥5, 
which suggests reduced and disturbed sleep in these patients. 
Among the individual components of PSQI, sleep latency was 
the most affected, followed by sleep quality and duration. Du-
ration of diabetes was the greatest predictor of sleep distur-
bances among our study sample, while age, gender, BMI, insu-
lin or OHA use or HbA1c did not correlate with sleep dysfunc-
tion. Mean duration of sleep per day was 6 hours and 15 min-
utes, suggesting that a majority of type 2 diabetics suffer from 
sleep disturbances.
  Sleep disturbances are more common among diabetics than 
they are in the general population. Almost 50% of these pa-
tients have sleep apnea [14]; among obese patients with type 2 
diabetes, the prevalence of sleep apnea has been estimated at 
86% [15]. Sleep disturbances and sleep loss are also implicated 
in insulin resistance, a precursor to type 2 diabetes. Individu-
als who sleep more than 8 hours per day or less than 7 hours 
per day are at a modestly increased risk of all-cause mortality, 
cardiovascular disease, and developing symptomatic diabetes 
[16].
  Sleep apnea and sleep-disordered breathing contribute to 
metabolic derangements such as glucose intolerance and insu-
lin resistance independent of obesity [3-9]; accumulating evi-
dence suggests that they may be independent risk factors for 
hypertension and cardiovascular disease [17-19]. However, 
the relationship between sleep-disordered breathing (SDB) 
and diabetes is not clearly understood. A few studies have at-
tempted to evaluate the cross-sectional relationship, but they 
have had mixed results. In their study, Reichmuth et al. [20] 
concluded that SDB contributes to weight gain and obesity; 
these changes lead to increased insulin resistance, which in 
turn increases the patient’s risk of developing diabetes. In a 
clinic-based study, Vgontzas and colleagues [8] found that pa-
tients with sleep-disordered breathing had significantly higher 
fasting glucose and insulin levels compared with a group of 
weight-matched control participants. They also suggested that 
the glucose intolerance and insulin resistance associated with 
sleep-disordered breathing may be intermediate in the puta-
tive causal pathway to increased cardiovascular morbidity and 
mortality [21,22].
  Stoohs et al. [5] reported that worsening insulin sensitivity 
and SDB in a group of 50 “healthy, normotensive individuals” 
was completely accounted for by their increased BMI. Another 
study [3] found a relationship between fasting insulin level 
and increasing apnea-hypopnea index (AHI) in patients with 
BMI of 29 or greater but not in those with lower BMI. In our 
study, BMI did not have a significant correlation with global 
PSQI score. However, our results showed a trend toward a pos-
itive association of BMI ≥25 kg/m
2 with global PSQI score 
(R
2=0.02), indicating that BMI may affect sleep quality in 
overweight and obese type 2 diabetes patients. This finding is 
in accordance with the study by Vorona et al. [23], who found 
a similar relationship. Our analysis also suggested that the 
choice of medications does not have a significant influence on 
sleep quality in type 2 diabetes patients.
  Interestingly in our study, duration of diabetes significantly 
correlated with global PSQI score. Patients with a longer dura-
tion of diabetes had poor sleep quality independent of other 
variables. The reason for this is unclear but could be due to 
multiple factors, including neuropathy and nocturia, which 
are more prevalent in long-term diabetics. We did not find a 
Table 4. Comparison of PSQI components based on medica-
tions 
PSQI component OHAs Insulin
Insulin & 
OHAs
P value
Subjective sleep quality 1.22±0.88 1.45±0.94 1.52±0.79 0.36 
Sleep latency  1.37±1.08 1.65±0.98 1.70±1.19 0.44 
Sleep duration  1.14±0.98 1.15±1.03 1.39±0.84 0.50 
Sleep efficiency  0.51±0.69 0.70±0.98 0.70±0.82 0.70 
Sleep disturbance 1.09±0.61 1.10±0.44 1.35±0.65 0.31 
Hypnotic medication 
use
0.27±0.73 0.65±1.18 0.60±1.19 0.62 
Daytime dysfunction 0.92±0.89 1.30±1.12 1.30±0.87 0.13 
PSQI global score 6.43±3.63 8.00±4.19 8.43±4.08 0.06 
Data are presented as mean±standard deviation.
PSQI, Pittsburgh sleep quality index; OHAs, oral hypoglycemic 
agents.74
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significant correlation between HbA1c and global PSQI score. 
However, in patients with uncontrolled diabetes (HbA1c ≥7%), 
a mild positive association existed between the two, indicating 
poor quality of sleep in these patients. The study by Nakajima 
et al. [24] supported our observations by reporting a short 
sleep duration in individuals with high HbA1c levels. Sleep 
deprivation in these patients may in turn worsen their diabetic 
state by 1) triggering the secretion of stress hormones and pro-
inflammatory cytokines, leading to glucose intolerance and 
decreased insulin sensitivity [8]; 2) increasing sympathetic 
nervous system activity [25,26], which may impair glucose 
regulation via the lipolytic effects of adrenergic stimulation of 
visceral adipose tissue [27]; and 3) decreasing levels of the sa-
tiety hormone leptin and increasing the hunger hormone 
ghrelin, thereby increasing hunger and food intake [28]. Re-
cent evidence also suggests that sleep durations of 6 hours or 
less or 9 hours or more are associated with increased preva-
lence of diabetes and impaired glucose tolerance (IGT) [29]. 
The experimental restriction of sleep to 4 hours per night for 6 
nights produced IGT in healthy young adults [30].
  A number of studies have shown that treatment of sleep 
disorders may help in attaining better glycemic control in type 
2 diabetics. Continuous positive airway pressure (CPAP) ther-
apy significantly improved insulin sensitivity in 40 patients 
with sleep apnea. This improvement was observed within 2 
days of treatment and was sustained over 3 months [31]. Insu-
lin responsiveness increased by 28% in patients with type 2 di-
abetes after 4 months of CPAP therapy [32]. In patients with 
type 2 diabetes, postprandial glucose levels were significantly 
reduced after approximately 3 months of CPAP therapy that 
had been initiated to treat sleep apnea. HbA1c levels were sig-
nificantly reduced in patients with HbA1c >7% [33]. Contin-
uous blood glucose monitoring of type 2 diabetes patients on 
CPAP therapy for an average of 41 days demonstrated lower 
and more stable nocturnal glucose levels [34].
  Based on the current evidence, a strong association exists 
between sleep and glucose regulation. Our study identified a 
higher prevalence of sleep dysfunction in type 2 diabetics, and 
there was a strong association between duration of diabetes 
and the quality of sleep in these individuals. Sleep latency was 
the most affected symptom among these patients. Our study 
reiterated the importance of sleep evaluation in type 2 diabetes 
patients, as better sleep quality in these patients may improve 
the overall prognosis of the disease by significantly reducing 
cardiovascular risks. Furthermore, treatment of sleep apnea 
improves insulin sensitivity and could benefit the metabolic 
profiles of these patients. 
  Our study has several limitations. First, we did not have a 
healthy non-diabetic control group in our study to facilitate a 
direct comparison. Second, we did not have polysomnograph-
ic measures of sleep in this study, so it was not possible to de-
tect sleep disorders like obstructive sleep apnea. Third, we 
could not exclude the possibility of confounding effects by un-
measured variables, such as a sedentary lifestyle or poor diet. 
Finally, we did not find a significant correlation of HbA1c or 
BMI with sleep quality, which can be attributed to the smaller 
sample size of our study.
  In summary, our study suggested that southeast Asian Indi-
an patients with type 2 diabetes had a higher prevalence of 
sleep dysfunction relative to the general population. Our anal-
ysis also indicated that the duration of diabetes was the great-
est predictor of sleep disturbances in diabetic patients. Identi-
fying sleep disturbances in this population and treating them 
early could reduce significant cardiovascular risk.
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